Summary of the Conference Call on Preclinical CRO Industry Industry Overview - The preclinical Contract Research Organization (CRO) sector is experiencing a significant surge in orders, with a full recovery expected by Q4 2025. Orders are projected to increase by tens of percentage points year-on-year in H1 2026, potentially doubling the order value due to both volume and price increases [1][2]. Core Insights and Arguments - **Service Price Recovery**: Rapid recovery in service prices has been noted, particularly in the safety evaluation sector, where discounts have narrowed from 50% to no discount, resulting in year-on-year price increases of several tens of percentage points. This price increase is expected to translate directly into profits [1][2]. - **Monkey Resource Supply Shortage**: A critical factor driving the increase in service prices is the shortage of monkey resources, exacerbated by slow import approval processes. This shortage has led to a dramatic rise in monkey prices, which in turn has pushed up service fees [3]. - **BD Transaction Activity**: The active business development (BD) transactions are concentrating research and development investments in the preclinical phase. High-value orders are expected to be fully reflected in financial reports by Q3 2026, with net profits anticipated to return to 2021 peak levels by Q1 2027 [1][4]. Future Outlook - **Order Sustainability**: There are no immediate concerns regarding order sustainability. Orders are expected to show strong performance in Q1 and Q2 of 2026, with projected year-on-year growth of several tens of percentage points. The overall order amount may double due to the combined effect of increased order volume and service price hikes [4]. - **Profit Margin Impact**: The rapid increase in order prices is expected to significantly enhance profit margins for related companies. The price improvement began in Q3 2025, with discounts narrowing from 50-60% to 80-90%. This price increase is anticipated to be reflected in financial statements starting Q3 2026, with some companies potentially reaching net profit levels close to the peak of 2021 by Q1 2027 [5][6]. Key Companies to Watch - **InnoCare Pharma**: Recommended due to its low correlation with the domestic market and strong order certainty in Q1 and Q2 of 2026. Its smaller market capitalization provides significant upside potential [7]. - **Zhaoyan New Drug**: Despite facing a reduction event, it presents a good entry point. The profit levels in 2027 are expected to match or exceed those of 2021, with considerable room for growth compared to previous peaks [7]. - **Medpace**: As a leading integrated preclinical service provider, it is currently benefiting from the focus on safety evaluation. As the industry continues to improve, its front-end services are expected to gain traction, revealing its performance elasticity [7]. Overall Market Trend - The current market situation is just the beginning, driven by improved BD conditions for innovative drugs in 2025. Although there have been significant stock adjustments due to rising monkey prices and corrections in the innovative drug sector, the current position offers a favorable entry point for investors. Continued healthy development of the Chinese innovative drug industry is expected to benefit domestic CRO companies, with potential for greater valuation expansion if orders remain strong in the second half of the year [8][9].

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% year-on-year [9] - The growth in revenue is primarily driven by the strong performance of model animals and preclinical CRO services, with model animal revenue reaching 622 million RMB, up 59.86% year-on-year, and preclinical CRO service revenue increasing by 75.24% to 352 million RMB [9] - The company is expected to continue its robust growth trajectory, with projected revenues of 1.847 billion RMB in 2026, 2.416 billion RMB in 2027, and 3.144 billion RMB in 2028, corresponding to growth rates of 34.0%, 30.8%, and 30.1% respectively [2][10] Financial Summary - In 2025, the company reported a gross margin of 75.83% and a net profit margin of 12.56% [10] - The earnings per share (EPS) for 2025 was 0.39 RMB, with projections of 0.76 RMB in 2026, 1.19 RMB in 2027, and 1.68 RMB in 2028 [2][10] - The price-to-earnings (P/E) ratio is projected to decrease from 133 in 2025 to 31 by 2028, indicating an improving valuation as earnings grow [2][10] Business Growth Drivers - The company is enhancing its global leadership in innovative animal models, with plans to expand production capacity significantly by the end of 2026 [9] - The preclinical CRO business is diversifying its service offerings and expanding its global operational network, with infrastructure developments planned for its Boston subsidiary in 2026 [9] - The antibody development platform is leveraging AI and automation to enhance antibody discovery, with over 350 collaboration agreements signed, and several projects entering clinical trials [9]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [9] - The growth in revenue is primarily driven by the robust performance of the model animals and preclinical CRO services, with model animal revenue reaching 622 million RMB, up 59.86% year-on-year, and preclinical CRO service revenue increasing by 75.24% to 352 million RMB [9] - The company is expected to continue its strong growth trajectory, with projected revenues of 1.847 billion RMB in 2026, 2.416 billion RMB in 2027, and 3.144 billion RMB in 2028, corresponding to growth rates of 34.0%, 30.8%, and 30.1% respectively [2] Financial Performance Summary - In 2025, the company reported a net profit of 173 million RMB, with a significant increase in R&D expenses to 438 million RMB, reflecting a 35.23% year-on-year growth [9] - The earnings per share (EPS) for 2025 was 0.39 RMB, with projections of 0.76 RMB in 2026, 1.19 RMB in 2027, and 1.68 RMB in 2028 [2] - The price-to-earnings (P/E) ratio is projected to decrease from 133 in 2025 to 31 by 2028, indicating an improving valuation as earnings grow [2] Business Growth Drivers - The company is enhancing its global leadership in innovative animal models, with plans to expand production capacity significantly by the end of 2026 [9] - The preclinical CRO business is expanding its service offerings and global network, with plans to enhance infrastructure in Boston in 2026 [9] - The antibody development platform is expected to leverage AI and automation, with over 350 collaboration agreements signed, and several projects entering clinical trials [9]

Investment Rating - The report assigns a "Buy" rating for the company, Yinos (688710.SH), for the first time [2]. Core Insights - Yinos has established itself as a leading player in the preclinical CRO sector, backed by state-owned capital, and is expected to see a recovery in performance due to stable growth in orders and the release of new production capacity [6][7]. - The company is well-positioned in high-growth areas such as ADC, small nucleic acid drugs, and CGT, with its international strategy beginning to yield results, potentially driving future growth [6][8]. - Financial projections indicate a return to profitability with expected net profits of -30 million, 116 million, and 191 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of -0.22, 0.82, and 1.36 yuan [6][9]. Summary by Sections 1. Preclinical Safety Evaluation as Core, State-Owned Empowerment - Yinos, established in 2010, is a subsidiary of China National Pharmaceutical Group and has achieved multiple GLP certifications, positioning itself as a provider of high-quality biopharmaceutical R&D services [17][19]. - The company has developed a comprehensive service platform covering early drug evaluation, non-clinical efficacy studies, and safety evaluations, focusing on non-clinical safety evaluation as its core business [19][39]. 2. Policy and Funding Drive Innovation Drug Recovery - The domestic CRO industry is experiencing a recovery driven by favorable policies and increased funding, with significant government support for innovative drug development [7][51]. - The report highlights that the Chinese pharmaceutical industry is transitioning from generic to innovative drugs, supported by a series of policies aimed at enhancing the development environment for innovative drugs [51][52]. 3. Strong Capabilities, New Technologies, and Internationalization - Yinos has modern facilities and a large research team, enabling it to provide comprehensive R&D services that meet both domestic and international standards [8][17]. - The company has seen a steady increase in the number of clients served, with over 950 pharmaceutical companies and research institutions benefiting from its services [32][34]. 4. Financial Summary and Valuation Indicators - The company’s revenue is projected to recover, with expected revenues of 812 million, 1,074 million, and 1,377 million yuan for 2025, 2026, and 2027 respectively, reflecting a growth trajectory [9][37]. - The report indicates that the company’s gross margin is expected to stabilize and improve as the industry recovers, with a projected gross margin of 32.7% in 2026 [47][48]. 5. Market Outlook and Growth Potential - The CRO market in China is expected to grow significantly, with projections indicating a market size of 140.6 billion yuan in 2025, maintaining a growth rate of over 15% [69]. - The report emphasizes that the increasing demand for CRO services is driven by the rising R&D expenditures of large pharmaceutical companies, which are projected to reach 190 billion USD by 2024 [60][63].

Investment Rating - The investment rating for the company is "Buy" (initial coverage) [6] Core Insights - The company has a strong foundation in the preclinical CRO business, with a solid track record and promising future prospects. It is positioned well in high-growth areas such as ADC, small nucleic acid drugs, and CGT, with its international strategy beginning to show results [6][7] - The company is expected to see a recovery in performance due to the gradual release of new capacity from fundraising projects and steady growth in existing and newly signed orders. Long-term growth is anticipated, with projected net profits for 2025-2027 being -30 million, 116 million, and 191 million yuan, respectively [6][9] Summary by Sections 1. Preclinical Safety Evaluation as Core, State-Owned Capital Empowering Market Leaders - The company, established in 2010, is a subsidiary of China National Pharmaceutical Group and has achieved multiple GLP certifications, positioning itself as a leading provider of high-quality biopharmaceutical R&D services [17][19] - The company has developed a comprehensive service platform covering early drug evaluation, non-clinical efficacy research, and clinical sample analysis, with modern facilities and a large research team [17][19] 2. Policy and Funding Synergy Driving Innovation Drug Recovery - The domestic CRO industry is showing signs of recovery, supported by favorable policies and increased funding for innovative drugs. The company is well-positioned to benefit from this growth [7][50] - Recent policies have created a supportive environment for innovative drug development, enhancing the growth certainty for the CRO industry [51][52] 3. Strong Capabilities, New Technologies, and Internationalization - The company has established a competitive international service capability, with a modern facility of approximately 74,000 square meters and a research team of over 1,000 people [8][17] - Continuous investment in innovation and the establishment of specialized technology platforms are expected to support long-term growth [8][39] 4. Financial Summary and Valuation Indicators - The company’s revenue for 2023 is projected at 1,038 million yuan, with a year-on-year growth of 20.3%. However, a decline is expected in 2025, with revenue estimated at 812 million yuan [9] - The projected net profit for 2025 is -30 million yuan, with a significant recovery anticipated in subsequent years [9] 5. Order Growth and Market Position - The company has seen a robust increase in new orders, with a total of 11.35 billion yuan in new signed orders for 2025, reflecting a year-on-year growth of 38.62% [34] - The company’s ability to secure a substantial order backlog and new contracts is a positive indicator for future performance [34][39]

Investment Rating - The report maintains a strong rating for the CXO sector, indicating a positive outlook for investment opportunities in the industry [4]. Core Insights - The global and Chinese healthcare investment markets are expected to recover by 2025, with record highs in licensing transactions and upfront payments for Chinese innovative drugs, indicating enhanced global competitiveness of Chinese pharmaceutical companies [1][2]. - The CXO market is projected to experience stable growth by 2026, driven by a recovery in downstream demand and a reduction in geopolitical risks due to amendments in the U.S. Biodefense Act [1][3]. Summary by Sections 1. CXO Market Growth - The global and Chinese preclinical CRO markets are forecasted to reach $33.25 billion and 52.86 billion RMB respectively by 2026, with the clinical CRO market expected to reach $73.2 billion and 59.8 billion RMB [2][19]. - The global CDMO market is anticipated to grow to $118.9 billion by 2026 and $338.5 billion by 2033, with China's CDMO market expected to reach 137 billion RMB by 2026 [2][36]. 2. Industry Concentration and Competitive Landscape - The industry is witnessing accelerated concentration, with leading companies like WuXi AppTec and Tigermed establishing strong competitive advantages through integrated service offerings [3][53]. - By 2025, WuXi AppTec's revenue is projected to reach 45.456 billion RMB, with a net profit margin significantly above the industry average [3][53]. 3. Investment and Financing Trends - In 2025, the global healthcare sector completed 1,930 financing transactions totaling $63.2 billion, with a year-on-year increase of 8.6% [56]. - China’s healthcare sector saw 797 financing transactions amounting to $9.7 billion, reflecting a 32.9% increase year-on-year [58]. 4. Policy Environment and Risk Mitigation - The revised U.S. Biodefense Act is expected to alleviate immediate impacts on the domestic biopharmaceutical industry, as it no longer explicitly names specific companies [74][75]. - The market has transitioned from panic pricing to rational pricing, indicating a recovery in investor sentiment following the enactment of the revised Biodefense Act [76]. 5. Valuation and Performance Analysis - The CXO sector saw a 55.26% increase in 2025, outperforming the Shanghai Composite Index, with a current PE ratio of 26.75, indicating a significant valuation premium over historical averages [78][79]. - The sector's revenue for the first three quarters of 2025 reached 73.788 billion RMB, marking a 10.08% increase year-on-year, while net profit grew by 51.90% [80][85].

Summary of Conference Call on Experimental Monkey Supply and Demand Industry Overview - The report focuses on the experimental monkey supply and demand dynamics, particularly in the context of preclinical Contract Research Organizations (CROs) [1][2] - The global supply of experimental monkeys is tight, with a projected shortfall of nearly 10,000 monkeys in China and 20,000 to 30,000 in the U.S. by 2024 [1][4] Key Points and Arguments Supply Constraints - China's experimental monkey population is aging, with 80% of breeding females over 8 years old in 2023, severely limiting breeding capacity [1][6] - The high prices from 2019 to 2022 led to significant loss of breeding monkeys, and the long breeding cycle of the species further complicates supply recovery [1][6] - Importing monkeys from overseas faces multiple constraints, including strict approvals and complex quarantine requirements, which hinder short-term improvements in supply [1][7] Demand Drivers - The demand for experimental monkeys is expected to grow significantly due to improved investment in innovative drugs, with projections of 45,000 to 50,000 monkeys needed in China from 2026 to 2028 [1][11] - The increase in IND (Investigational New Drug) applications is anticipated to continue, reflecting a recovery in preclinical safety evaluation demand [1][11] Price Trends - Monkey prices are expected to rise again, potentially reaching previous highs of over 200,000 yuan per monkey by 2026-2028 due to the expanding supply-demand gap [1][12][13] - The price fluctuations have historically ranged from 3,000 yuan to over 200,000 yuan, with recent trends indicating a recovery from lows of 80,000 to 100,000 yuan [1][4] Impact on CROs - The profitability of preclinical CROs is expected to improve as monkey prices rise, with net profit margins projected to rebound from negative values to around 10% by 2025 [1][14] - The fair value changes related to monkey assets will significantly impact companies like Zhaoyan New Drug, which is expected to see a profit contribution of approximately 450 to 500 million yuan from fair value changes in 2025 [1][15][16] Additional Important Insights - The report highlights the potential impact of U.S. trade changes with Cambodia, which could further strain China's monkey supply as U.S. demand may siphon off available resources [1][9] - The analysis indicates that unless there is a large-scale opening of monkey imports, the supply issues in China will persist through 2026-2027 [1][10] - The report emphasizes the importance of monitoring the performance of key CROs such as WuXi AppTec, Kanglong Chemical, and Medpace, as they are expected to benefit from the evolving market dynamics [1][17]

Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [10]. - The growth was driven by both domestic recovery and overseas expansion, with significant contributions from model animals and preclinical CRO services [10]. - The antibody development platform is progressing well, with numerous collaborations that are expected to enhance future growth potential [10]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 1.379 billion RMB (2025), 1.849 billion RMB (2026), and 2.422 billion RMB (2027), with growth rates of 40.6%, 34.1%, and 31.0% respectively [3][10]. - Net profit forecasts for the same period are 173 million RMB (2025), 335 million RMB (2026), and 528 million RMB (2027), with growth rates of 416.4%, 93.3%, and 57.7% respectively [3][10]. - The earnings per share (EPS) are projected to be 0.39 RMB (2025), 0.75 RMB (2026), and 1.18 RMB (2027) [3][10]. Business Segments - The domestic revenue for the first half of 2025 was 199 million RMB, showing a year-on-year increase of 70.54%, while overseas revenue reached 421 million RMB, up by 43.59% [10]. - Model animals and preclinical CRO services were the main growth drivers, with model animal revenue at 274 million RMB (up 56.13%) and preclinical CRO service revenue at 155 million RMB (up 90.10%) in the first half of 2025 [10]. - The company launched over 400 humanized mouse models in 2025, reinforcing its leading position in the humanized animal model sector [10].

Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [10]. - The growth was driven by both domestic recovery and overseas expansion, with significant contributions from the model animals and preclinical CRO services [10]. - The antibody development segment is progressing well, with numerous collaborations that are expected to enhance future growth potential [10]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 1.379 billion RMB (2025), 1.849 billion RMB (2026), and 2.422 billion RMB (2027), with growth rates of 40.6%, 34.1%, and 31.0% respectively [3][11]. - Net profit forecasts for the same period are: 173 million RMB (2025), 335 million RMB (2026), and 528 million RMB (2027), with growth rates of 416.4%, 93.3%, and 57.7% respectively [3][11]. - The earnings per share (EPS) are projected to be 0.39 RMB (2025), 0.75 RMB (2026), and 1.18 RMB (2027) [3][11]. Business Segments - The model animals segment saw a revenue of 274 million RMB in the first half of 2025, growing by 56.13%, while preclinical CRO services generated 155 million RMB, marking a 90.10% increase [10]. - The company launched over 400 humanized mouse models in 2025, reinforcing its leading position in the humanized animal model market [10]. - The preclinical CRO services are experiencing rapid growth, particularly in pharmacology and efficacy research, with significant increases in various service areas [10]. Collaborations and Partnerships - As of the first half of 2025, the company signed approximately 280 drug collaboration agreements with around 120 pharmaceutical companies, including 80 new agreements in the first half of 2025 [10]. - A notable collaboration involves the ADC candidate IDE034, which has entered Phase I clinical trials, with potential milestone payments of up to 406.5 million USD [10].

Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]